Daily Digest
Daily Digest
Company hub
Everything Pomegra has published on PFE: 12 news articles and 13 market briefs, newest first.
Eli Lilly (LLY) won China's first oral GLP-1 weight-loss pill nod, with sales up 39% last quarter.
1h ago
Moderna (MRNA) raised its 2026 revenue growth outlook to 15%-25% from up to 10% as quarterly sales rose 29%
6d ago
AMD (AMD) reports Tuesday; Super Micro (SMCI) pre-announced up to $19.5B in sales amid AI demand doubts.
Nov 2
Alnylam (ALNY) fell to $174 as demand for heart drug Amvuttra slowed and Medicare pricing changes loomed
Oct 30
Moderna (MRNA) slid another 1.3% Friday to $200 as investors weighed a 42% cut in melanoma recurrence risk.
Oct 26
Moderna (MRNA) fell as Merck slipped up to 3.9% after leaked data showed a 42% lower melanoma relapse risk.
Oct 22
Eli Lilly (LLY) jumped 4.7% to a record as the Dow closed near 52,514, the Nasdaq stayed flat and oil fell.
Oct 20
Moderna (MRNA) is up over 600% this year after joining the Nasdaq-100, with Phase 3 data due Saturday.
Oct 19
Moderna (MRNA) is up more than 540% in 2026 as investors await Phase 3 cancer vaccine data on Oct. 24.
Oct 8
Moderna (MRNA) is up nearly 600% in 2026 as traders position for full October 24 melanoma trial results. Latest MRNA stock news and what to watch.
Oct 5
Vaxcyte (PCVX) closed at $73.82 as its VAX-31 shot held up against Pfizer's and Merck's shots in a large trial
Oct 5
Moderna (MRNA) sank from $203.46 to about $191 as Citi said a 222% rally assumes unrealistic cancer sales.
Sep 30
The 100% tariff now hits drugmakers without pricing deals; Pfizer (PFE) and 16 peers are exempt to 2029.
Sep 30
Pfizer (PFE) reports Q3 2026 results today with shares near a 52-week high as investors weigh newer-product growth, oncology gains and a looming patent cliff.
Moderna (MRNA) shares fell another 8% on Monday after leaked melanoma vaccine data showed a 42% cut in recurrence or death risk, extending a selloff in biotech cancer stocks.
Moderna rose 7% to $241.89 and Bristol Myers Squibb 5% as biotech cancer stocks rallied before Phase 3 melanoma vaccine data in Madrid on October 24.
Moderna rose 14% to $225, its highest since January 2022, as a planned federal cancer vaccine push also lifted Pfizer, BioNTech and Merck shares on Friday.
Vaxcyte (PCVX) shares jumped about 50% after VAX-31 met every primary endpoint in a pivotal Phase 3 trial against Pfizer's Prevnar 20 and Merck's Capvaxive.
Moderna shares fell about 6% to near $190 after Citi cut the stock to Sell with an $80 target, saying a 223% rally overshot what cancer vaccine sales can justify.
Pfizer (PFE) climbs to its highest close since October 2024 while Solventum posts a 52-week record as capital rotates into defensive dividend-paying healthcare.
Pfizer's management says strong operating cash flows underpin the company's commitment to maintain its dividend after the yield climbed to the highest level in the S&P 500.
Pfizer's $4.6 billion semi-annual dividend commitment draws scrutiny as patent expirations threaten up to $17 billion in annual revenue through 2030, raising questions about the long-term…
Q32 Bio stock jumped 83% on July 13 after Phase 2a data showed bempikibart cut hair-loss severity scores by 35% in patients with severe alopecia areata, including those who had failed JAK inhibitors.
Moderna shares surged 48% in June as an FDA flu vaccine endorsement and sector rotation away from semiconductors lifted healthcare and biotech stocks broadly.
Germany's Chancellor insists Washington must abide by the existing US-EU trade agreement after the U.S. Trade Representative launches a Section 301 pharmaceutical probe targeting Berlin's drug…
Pomegra